Answers are grounded in this paper and cite their sources.
Field update highlights the need for monitored antidepressant use in Alzheimer’s disease, suggesting new trial directions.
Monoaminergic antidepressants in AD should not be abandoned but repositioned as time‑limited, closely monitored options for clearly defined, functionally impairing depressive syndromes, embedded in multimodal care rather than used as default, long‑term treatment for non‑specific distress. Future priorities include biomarker‑stratified AD depression trials, evaluation of interactions with anti‑amyloid therapies and rigorous testing of non‑monoaminergic interventions.
No takes yet. Share an insight, caveat, or question.
Prelog et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: